Evidence map›Paper›PMID 26049061›Full record

ArticleBehavioural brain research2015

Analysis of gait in rats with olivocerebellar lesions and ability of the nicotinic acetylcholine receptor agonist varenicline to attenuate impairments.

C S Lambert, R M Philpot, M E Engberg, B E Johns, L Wecker

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Behavioural brain research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 6 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

C S LambertDepartment of Molecular Pharmacology and Physiology, University of South Florida Morsani College of Medicine, Tampa, FL, USA; Laboratory of Neuropsychopharmacology, Department of Psychiatry and Behavioral Neurosciences, University of South Florida Morsani College of Medicine, Tampa, FL, USA.
R M PhilpotLaboratory of Neuropsychopharmacology, Department of Psychiatry and Behavioral Neurosciences, University of South Florida Morsani College of Medicine, Tampa, FL, USA.
M E EngbergLaboratory of Neuropsychopharmacology, Department of Psychiatry and Behavioral Neurosciences, University of South Florida Morsani College of Medicine, Tampa, FL, USA.
B E JohnsLaboratory of Neuropsychopharmacology, Department of Psychiatry and Behavioral Neurosciences, University of South Florida Morsani College of Medicine, Tampa, FL, USA.
L WeckerDepartment of Molecular Pharmacology and Physiology, University of South Florida Morsani College of Medicine, Tampa, FL, USA; Laboratory of Neuropsychopharmacology, Department of Psychiatry and Behavioral Neurosciences, University of South Florida Morsani College of Medicine, Tampa, FL, USA; Department of Neurology, University of South Florida Morsani College of Medicine, Tampa, FL, USA; School of Physical Therapy and Rehabilitation Sciences, University of South Florida Morsani College of Medicine, Tampa, FL, USA. Electronic address: lwecker@health.usf.edu.
University of South Florida · US

Funding

Neuronal nicotinic receptor modulation and cerebellar ataxiasR01NS072114 · NINDS · UNIVERSITY OF SOUTH FLORIDA · PI WECKER, LYNN · 2011 to 2015
$1.7M
NINDS NIH HHS R01 NS072114NINDS NIH HHS R01NS072114
6 · The paper itself

Abstract

Studies have demonstrated that administration of the neuronal nicotinic receptor agonist varenicline to rats with olivocerebellar lesions attenuates balance deficits on a rotorod and balance beam, but the effects of this drug on gait deficits have not been investigated. To accomplish this, male Sprague-Dawley rats were trained to walk on a motorized treadmill at 25 and 35 cm/s and baseline performance determined; both temporal and spatial gait parameters were analyzed. A principal component analysis (PCA) was used to identify the key components of gait, and the cumulative gait index (CGI) was calculated, representing deviations from prototypical gait patterns. Subsequently, animals either remained as non-lesioned controls or received injections of 3-acetylpyridine (3-AP)/nicotinamide to destroy the climbing fibers innervating Purkinje cells. The gait of the non-lesioned group was assessed weekly to monitor changes in the normal population, while the gait of the lesioned group was assessed 1 week following 3-AP administration, and weekly following the daily administration of saline or varenicline (0.3, 1.0, or 3.0mg free base/kg) for 2 weeks. Non-lesioned animals exhibited a 60-70% increased CGI over time due to increases in temporal gait measures, whereas lesioned animals exhibited a nearly 3-fold increased CGI as a consequence of increases in spatial measures. Following 2 weeks of treatment with the highest dose of varenicline (3.0mg free base/kg), the swing duration of lesioned animals normalized, and stride duration, stride length and step angle in this population did not differ from the non-lesioned population. Thus, varenicline enabled animals to compensate for their impairments and rectify the timing of the gait cycle.

Indexed as

AnimalsAtaxiaBiomechanical PhenomenaCerebellumDisease Models, AnimalDose-Response Relationship, DrugGaitMaleNiacinamideNicotinic AgonistsOlivary NucleusPrincipal Component AnalysisPyridinesRandom AllocationRats, Sprague-DawleyVarenicline3-acetylpyridineNiacinamideNicotinic AgonistsPyridinesVareniclineAtaxiaCumulative gait indexGaitPrincipal component analysisVarenicline

Identifiers

PMID26049061
PMCPMC4497862
OpenAlexW612130858

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.